Glycolytic alterations as biomarkers in polycystic kidney disease: A study using a PKD1 knockout model in NRK ‐ 52E rat kidney epithelial cells
Physiological Reports · 2026-03 · 14 (6)
DOI: 10.14814/phy2.70816 ↗At a glance
Journal article in Physiological Reports, published online on 2026-03-19. Written by Ida Kjær Mieritz and 5 co-authors. Institution: The MR Research Center, Dept. of Clinical Medicine, Aarhus University, Aarhus N, Denmark. Major MEDLINE topics: Epithelial Cells, Glycolysis, Polycystic Kidney Diseases, TRPP Cation Channels. 38 references. The full text is freely available (open access, CC BY 4.0). Funded by: Lundbeckfonden (Lundbeck Foundation), Novo Nordisk Fonden (NNF), The Danish Cancer Society.
Abstract (original language)
Polycystic kidney disease (PKD) is a genetic disorder characterized by the formation of fluid‐filled cysts in the kidneys, often resulting in progressive renal impairment. Mutations in the PKD1 gene represent the predominant genetic cause of autosomal dominant PKD. Here, we investigated how PKD1 knockout affects glycolytic metabolism in NRK‐52E kidney epithelial cells using dynamic nuclear polarization (DNP)‐enhanced magnetic resonance spectroscopy (MRS) with hyperpolarized [1‐ 13 C]pyruvate. PKD1 knockout NRK‐52E kidney epithelial cells showed a significantly elevated pyruvate‐to‐lactate conversion as measured by hyperpolarized [1‐ 13 C]pyruvate (HP‐MRS) and significantly increased lactate levels in culture medium, accompanied by upregulated lactate dehydrogenase (LDH) gene expression and enzymatic activity. Monocarboxylate transporter (MCT) expression was selectively altered (significant downregulation of MCT2 and MCT3; MCT1 not significantly changed). Pyruvate dehydrogenase (PDH) activity and transcript levels did not differ between groups. These results demonstrate glycolytic reprogramming associated with PKD1 deficiency and support hyperpolarized pyruvate MRS as a sensitive metabolic biomarker for detecting such alterations in real‐time. These findings identify glycolytic remodeling as a robust metabolic consequence of PKD1 loss and demonstrate that HP‐[1‐ 13 C]pyruvate MRS provides a flux‐level biomarker suitable for real‐time metabolic characterization.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- The MR Research Center, Dept. of Clinical Medicine, Aarhus University, Aarhus N, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
ORCID profiles: Lotte Bonde Bertelsen
Funding
- Lundbeckfonden (Lundbeck Foundation)
- Novo Nordisk Fonden (NNF)
- The Danish Cancer Society
- Karen Elise Jensens Fond (Karen Elise Jensen Foundation)
- Innovation Fund Denmark
- Lundbeck Foundation
- Kræftens Bekæmpelse
- Innovationsfonden
Cite
APA
Mieritz, I. K., Laustsen, C., Axelgaard, E., Dorset, S. R., Bak, R. O., & Bertelsen, L. B. (2026). Glycolytic alterations as biomarkers in polycystic kidney disease: A study using a PKD1 knockout model in NRK ‐ 52E rat kidney epithelial cells. Physiological Reports, 14(6). https://doi.org/10.14814/phy2.70816
Vancouver
Mieritz IK, Laustsen C, Axelgaard E, Dorset SR, Bak RO, Bertelsen LB. Glycolytic alterations as biomarkers in polycystic kidney disease: A study using a PKD1 knockout model in NRK ‐ 52E rat kidney epithelial cells. Physiological Reports. 2026;14(6). doi:10.14814/phy2.70816
BibTeX
@article{Mieritz2026,
author = {Mieritz, Ida Kjær and Laustsen, Christoffer and Axelgaard, Esben and Dorset, Sofie Rahbek and Bak, Rasmus O and Bertelsen, Lotte Bonde},
title = {Glycolytic alterations as biomarkers in polycystic kidney disease: A study using a PKD1 knockout model in NRK ‐ 52E rat kidney epithelial cells},
journal = {Physiological Reports},
year = {2026},
volume = {14},
number = {6},
doi = {10.14814/phy2.70816}
}
EUVIMED